uploads/2018/08/Chart-002-1.jpg

Examining Amgen’s Revenue Trend in Q2 2018

By

Updated

Amgen’s revenue

As we discussed earlier, Amgen (AMGN) reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017.

The chart above compares Amgen’s revenues since the first quarter of 2017.

Article continues below advertisement

Second-quarter revenue

Amgen surpassed analysts’ estimates for EPS and revenue in the second quarter, reporting non-GAAP (generally accepted accounting principles) EPS of $3.83 on revenue of ~$6.1 billion compared to the estimate of $3.54 on revenue of $5.7 billion.

During the quarter, the company’s product sales increased 2% to $5.679 billion compared to $5.574 billion in the second quarter of 2017. Its other revenue increased to $380 million in the quarter compared to $236 million in the second quarter of 2017.

Geographical performance

The company’s revenue from US markets decreased marginally to $4.37 billion during the second quarter compared to $4.39 billion in the second quarter of 2017. Its major revenue contributors in the US market were Enbrel, Neulasta, Prolia, Xgeva, Sensipar/Mimpira, Epogen, and Aranesp.

Its revenue in the markets in the rest of the world reported a 10.4% rise to $1.31 billion during the quarter compared to $1.19 billion in the second quarter of 2017. Its major revenue contributors in the rest of the world included the drugs Aranesp, Prolia, Neulasta, Xgeva, Kyrpolis, and Vectibix.

The VanEck Vectors Biotech ETF (BBH) holds 9.8% of its total investments in Amgen, 8.7% in Gilead Sciences (GILD), 5.9% in Biogen (BIIB), and 5.5% in Allergan (AGN).

Advertisement

More From Market Realist